Analysis of U.S. Patent 9,198,882: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 9,198,882?
U.S. Patent 9,198,882, granted on December 1, 2015, covers methods and compositions for the treatment of chronic obstructive pulmonary disease (COPD) through inhaled administration of PDE4 inhibitors. The patent aims to protect specific formulations and dosing regimens that improve lung function and reduce exacerbations in COPD patients.
Key aspects of the scope:
- Claims focus on inhalation-based formulations of selective phosphodiesterase 4 (PDE4) inhibitors.
- Target indications include COPD and related respiratory diseases.
- Delivery methods specify inhalation, including devices such as dry powder inhalers (DPI) and metered-dose inhalers (MDI).
- Formulation characteristics involve specific particle sizes, concentrations, and dosing schedules that optimize therapeutic efficacy and minimize side effects.
- Novelty resides in particular combinations of PDE4 inhibitor compounds with inhalation delivery techniques, emphasizing improved bioavailability and reduced systemic exposure.
What are the main claims of U.S. Patent 9,198,882?
The patent contains 26 claims, with claims 1, 2, and 26 being independent. The scope of these claims can be summarized as follows:
Independent Claims:
- Claim 1: A method of treating COPD by administering a PDE4 inhibitor via inhalation, with a specified dose range and particle size.
- Claim 2: A pharmaceutical composition comprising a PDE4 inhibitor and an inhalation carrier, with particular particle size and dosing parameters.
- Claim 26: A device configured for delivering the composition described, characterized by specific flow rates, particle sizes, and dose delivery features.
Dependent Claims:
Dependent claims specify formulations with particular PDE4 inhibitors (e.g., roflumilast, other selective PDE4 inhibitors), specific excipients, or particular inhaler device features that optimize delivery. These narrow the scope but reinforce the core protection around inhaled PDE4 inhibitors for COPD.
Key claim elements:
- Use of inhaled PDE4 inhibitors.
- Specific dosing regimens (e.g., once or twice daily).
- Particle size range of 1-5 micrometers for optimal alveolar deposition.
- Formulations that enhance systemic safety profile compared to oral PDE4 inhibitors.
How does the patent landscape for PDE4 inhibitors in respiratory diseases look?
Major players and patent filings:
- GlaxoSmithKline (GSK): Holds a broad portfolio including the drug Roflumilast, with multiple patents covering formulations, delivery methods, and treatment regimens.
- Pfizer: Filed patents covering PDE4 inhibitors for COPD, targeting specific chemical structures and inhalation delivery.
- Teijin Pharma and Others: Filed patents related to novel PDE4 inhibitor compounds with improved selectivity and reduced side effects.
Patent family and expiration timeline:
| Patent Family |
Filing Date |
Expiration Year |
Key Inventions |
| GSK (including 9,198,882) |
2012 |
2032 |
Inhalation formulations and delivery systems for PDE4 inhibitors |
| Pfizer |
2010 |
2030 |
Chemical structures and targeted delivery methods |
| Teijin |
2013 |
2033 |
Novel PDE4 compounds and methods of use |
Patent overlaps:
- Multiple patents cover similar formulations but differ in particle size, chemical structure, or device configuration.
- Cross-licensing exists in some territories, but patent disputes can arise over fundamental delivery methods.
Patent challenges:
- Prior art includes oral PDE4 inhibitors and inhalation devices existing before 2010.
- Claims are narrowed to specific particle sizes and delivery parameters to avoid invalidation risks.
- Recent filings seek to improve on side effect profiles like nausea by refining formulations.
How does this patent fit in the broader patent landscape?
U.S. Patent 9,198,882 fits into a strategic patent cluster held mainly by GSK, with coverage focusing on inhaled PDE4 inhibitors for COPD. It acts as a cornerstone patent for GSK’s inhalation product pipeline, including formulations like DTO (dry powder inhalers) containing roflumilast. Its claims are consistent with innovations seeking to improve target delivery and systemic safety.
Key considerations:
- Its niche focus on particle size and inhalation method limits freedom to operate but provides a robust defensive position.
- Competitors hold related patents on chemical compounds and alternative delivery systems.
- The patent's expiration in 2032 aligns with ongoing patent filings aiming to extend protection via local patent offices or supplementary protections.
Conclusions
U.S. Patent 9,198,882 claims specific inhaled formulations and delivery methods for PDE4 inhibitors targeting COPD. Its scope emphasizes particle size, dosing regimen, and device features that distinguish it from prior art. The patent landscape remains highly competitive, centered around chemical innovation and delivery systems patents, with GSK leading the segment.
Key Takeaways
- The patent protects inhaled PDE4 inhibitor formulations with specific particle sizes (1-5 micrometers).
- Core claims cover both compositions and delivery devices for COPD treatment.
- The patent landscape involves multiple key players, with overlapping claims refined to avoid invalidation.
- Patent protection extends until around 2032, with ongoing filings targeting improved formulations.
- Rapid innovation in delivery devices and formulations will shape future patent strategies.
FAQs
1. What chemical PDE4 inhibitors are covered by U.S. Patent 9,198,882?
The patent primarily covers roflumilast and related selective PDE4 inhibitors optimized for inhalation.
2. Does the patent include claims on specific inhaler devices?
Yes. It covers inhalation devices designed for delivering the specified formulations with features like specific flow rates and particle sizes.
3. How does particle size impact the patent’s claims?
Particle size (1-5 micrometers) is critical for alveolar deposition, and the claims specifically cover formulations within this range to optimize efficacy and safety.
4. What is the primary therapeutic application?
Chronic obstructive pulmonary disease (COPD).
5. Are there similar patents for other respiratory indications?
Yes. Similar patents cover PDE4 inhibitors for asthma and other inflammatory respiratory conditions but focus on different formulations and delivery methods.
References
- U.S. Patent No. 9,198,882. (2015). Methods and compositions for treatment of COPD using inhaled PDE4 inhibitors.
- Patent landscape sources. (2019-2023). Patent databases and industry reports tracking PDE4 inhibitor patents.
- GSK’s inhalation patent portfolio. (2022). Public patent portfolios and filings related to COPD treatments.
[1] U.S. Patent and Trademark Office. (2015). Patent No. 9,198,882.
